The growth of the smart inhalers market is mainly due to the rising prevalence of COPD and asthma. The increase in the prevalence of COPD and asthma is largely due to increased air pollution from both natural phenomena and anthropogenic sources. Two main air pollutants that can severely trigger asthma are ozone in smog and particulate matter in smog, haze and dust. As ozone and particulate matter in the air increase, the likelihood of developing asthma symptoms increases at an alarming rate. Hence, the surge in air pollution is expected to directly lead to rising cases of asthma and COPD, thereby driving the growth of the market.

Inhalers are devices that use a person's breath to deliver medication directly to the lungs. This could benefit patients by delivering drugs directly to the site of disease, allowing the drug to have a greater impact on its intended target and limiting side effects when administered topically. Inhalers are used to treat a variety of conditions, the most common of which are those of the lungs and respiratory system. People with these diseases/conditions need medicines that reduce airway inflammation and obstruction, allowing them to breathe easier and more comfortably. Antibiotics have even been developed for use in inhalers, allowing antibiotics to be delivered directly to the site of infection within the lungs. Asthma and COPD are the two most common conditions requiring inhalation therapy.

Smart Inhaler Technology market size estimates and forecasts are provided in terms of sales volume (K units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Smart Inhaler Technology market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and other global crises.

Market Dynamics

Growth Factors:

Increasing worldwide demand for digital healthcare solutions
Since changing traditional medical protocols and increasing penetration of IoT in the healthcare and medical devices sector. Moreover, the increasing geriatric population coupled with the surge in respiratory disease incidences is driving the growth of smart inhalers across the world.

Worldwide demand for smart inhalers is increasing
On account of growing air pollution at an upsetting rate and the pulmonary disorders caused due to it. For instance, Air pollution kills an estimated 7 million people worldwide every year from acquaintance to fine particles in polluted air that lead to diseases such as stroke, heart disease, lung cancer, chronic obstructive pulmonary diseases, and respiratory infections, including pneumonia.

Market Driver

The increasing adoption of technological advances in the production of smart inhalers and in the enhancement of their capabilities has positive effects on the market growth. In addition, the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) significantly contributes to the growth of smart inhalers' market revenue. In recent years, the increasing prevalence of such chronic diseases has increased the demand for effective respiratory care. Increasing numbers of patients with respiratory diseases such as asthma and COPD are driving the demand for more inhalation devices. According to data published by the Asthma and Allergy Foundation of America (AAFA), an estimated 25 million persons in the United States suffer from asthma, which is also a leading chronic disease among children. According to the Centers for Disease Control and Prevention (CDC), COPD ranked sixth among the main causes of death in the United States in 2020. COPD impacts more than 15 million Americans and annually claims 150,000 lives. The increasing number of collaborations between pharmaceutical and software companies to provide advanced smart inhalers in response to the rising demand for such devices is expected to boost the growth rate of the market. A smart inhaler is considered part of the digital new-age technology used to enhance the management of respiratory diseases.

It is anticipated that the increasing adoption of Bluetooth-enabled smart inhaler devices will fuel the market's growth rate. Bluetooth technology also contributes to the expansion of the market for smart inhalers, where data can be transmitted to smartphones and a physician can monitor patient health records. It assists them in providing appropriate care for the patient. Asthma and other respiratory diseases are becoming more prevalent, which is also driving up demand for smart inhalers.

Market Restraints 

Presence of Replacement Manual Inhalers May Restrain Market Expansion  

Despite the growing advantages of smart inhalers, the availability of manual inhalers as a substitute product may impede market expansion to some degree. In addition, a lack of awareness among the population of developing economies regarding the use of digital inhalers is a significant factor impeding the growth of the smart inhaler market over the forecast period.

Industry News and Key Developments

• In February 2020, Teva Respiratory, LLC, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that the ArmonAir Digihaler (Inhalation Powder) has been approved by the US Food and Drug Administration. It is administered using Teva’s Digihaler device. It is approved for the treatment of asthma in patients aged 12 and up.
• In April 2020, AptarGroup, Inc. and Sonmol, a Chinese digital respiratory therapeutics company, collaborated to create a digital therapies and services platform for respiratory and other diseases. This collaboration will help to focus on early detection and prevention measures for chronic respiratory diseases, which will strengthen the case for smart inhalers and connected devices as platforms for improving patient health.
• In June 2020 Aptar Pharma partnered with Lupin Limited  to launch ADHERO, India's first connected device for metered-dose inhalers (MDI).
• In August 2020, Propeller Health collaborated with Novartis to connect the digital health platform to the medications Enerzair and Atectura Breezhaler, which will be distributed in Japan to treat uncontrolled asthma. The company’s digital health sensor will assist people in Japan in managing their health conditions via the Propeller app on their smartphones.

Market Segmentation

On the Basis of Type:

The market for smart inhalers is split up by product, use, distribution method, and region. Inhalers and nebulizers are the two main types of products on the market. The inhalers are further divided into dry powder inhalers (DPIs) and metered dose inhalers (MDIs). In 2021, the MDIs segment captured over 60% of the market. MDIs are gaining popularity because they are efficient and simple to use, delivering a fixed dose in a brief burst of sprays that are typically inhaled by the patient themselves. In September 2022, the U.K.-based research laboratory OzUK Limited partnered with H&T Presspart to introduce generic MDIs for conventional Asthma/COPD applications to the market for H&T Presspart's customers. The market is divided into dry powder inhalers (DPIs) and metered dose inhalers based on product classification. (MDIs).

The segment of dry powdered inhalers (DPIs) is anticipated to record the highest CAGR over the forecast period, at 18.6%. As a treatment for respiratory ailments, DPIs are now preferred over pressurized MDIs and nebulizers due to growing concerns about the environmental impact of inhaler devices that utilize chloroflouro carbons as propellants.

On the Basis of Application:

In 2021, hospitals made up more than 50.0% of the biggest share. Expanding public-private partnerships, rapid improvements in healthcare infrastructure, and easier access to healthcare services are all things that are likely to have a big effect on the hospital sector. Based on where smart inhalers will be used, the market is split into hospitals, home care settings, and other places.

Over the next few years, the home care settings group is expected to grow at the fastest rate, 20.2%. Since the cost of health care is going up, many people with CRDs prefer to get treatment at home. The growth of this segment is also likely to be helped by the fact that older patients are becoming more interested in home care.

By Distribution channels:

In 2021, more than 40.0% of the market was made up of hospital pharmacists. The business is growing because more people are getting older and more people are getting CRDs. People over 65 are often treated for a wide range of long-term respiratory illnesses, and they might buy their medicine from the hospital pharmacy. The market is divided into hospital pharmacies, retail pharmacies, and internet pharmacies based on how the drugs are sold.

During the forecast period, the retail pharmacies section is expected to grow at the fastest rate, 19.2%. Customers like retail pharmacies more because they are more comfortable, flexible, and easy to use. This is driving up the demand for retail pharmacies in the market. Industry growth is being helped by the fact that established pharmacies are quickly growing and updating their services in order to reach more customers.

On the Basis of Region:

Geographically, the global Smart Inhaler Technology market has been analyzed in various regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, Europe, and India. The global Smart Inhaler Technology region is dominating this market in the upcoming future.

North America dominated the global Smart Inhaler Technology Market and is expected to continue to do so during the forecast period. This is due to improved healthcare infrastructure and facilities, an increase in the number of patients suffering from asthma and COPD, the adoption of technologically advanced treatments, the presence of key players, and the region’s rising healthcare expenditure. However, Asia-Pacific is expected to grow significantly due to its large geriatric population, increase in disposable income, surge in healthcare spending, and various development activities. Furthermore, the Asia-Pacific Smart Inhaler Technology Market is expected to grow rapidly in India and China.

Market Key Players

3M, Abbott Laboratories, Propeller Health, Teva Pharmaceuticals, Adherium, Cohero Health, and others.

• 3M

3M is an American global company that started out as the Minnesota Mining and Manufacturing Company. It works in industry, worker safety, healthcare, and consumer goods. The company makes more than 60,000 products under different brands. These include adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products, electronic circuits, healthcare software, and optical films. It is based in Maplewood, Minnesota, which is near Saint Paul.

• Abbott Laboratories

Abbott Laboratories is an American multinational medical device and health care company with its offices in Abbott Park, Illinois, United States. In 1888, a doctor in Chicago named Wallace Calvin Abbott started the company to make well-known medicines. Today, the company sells medical devices, diagnostics, branded generic medicines, and nutritional goods. In 2013, it split off AbbVie, which is a company that makes drugs based on study. In 2015, the CEO of Abbott said that the company had been in India for more than a hundred years. In 2002, it became known as Abbott India Ltd.

Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip are all goods made by Abbott.

• Propeller Health

Propeller Health is a digital health company with the goal of helping people with chronic diseases take control of their health and live better lives. They power engaging, care-connected patient journeys and bring value together for all parties, including providers, payers, pharma, and other healthcare and life sciences organizations.

The Propeller Platform includes medical devices that have been approved by the FDA and have the CE mark, apps for consumers, help and coaching, and safe access to clinical data for monitoring by providers. Their precision method is made to encourage people to change their behaviors and keep track of how well they do that. The goals are to help people get the most out of their medications and help predict expensive flare-ups. Their digital-first chronic respiratory care platform has been shown to improve quality of life and clinical outcomes while lowering healthcare costs in more than 150 peer-reviewed abstracts and articles.

Their specialties are respiratory health, disease management, asthma, COPD, digitally-guided therapy, value based care, population health, remote monitoring, mobile health, digital therapeutics, sensors, mHealth, internet of things, digital health and chronic conditions.

• Teva Pharmaceuticals

Teva Pharmaceutical Industries Ltd., also called Teva Pharmaceuticals, is an Israeli multinational pharmaceutical company with its offices in Tel Aviv, Israel. Its main business is making generic drugs, but it also sells active pharmaceutical ingredients and, to a lesser degree, its own drugs. Teva Pharmaceuticals was the biggest company that made generic drugs until Pfizer, which is based in the US, passed it for a short time. Once Pfizer's generic drug business merged with Mylan at the end of 2020 to form the new company Viatris, Teva got back to being the market leader. Teva is the 18th biggest drug company in the world as a whole.

Teva has factories in Israel, the United States, Europe, Australia, and South America. The Tel Aviv Stock Exchange has Teva shares for sale. The company is part of the Pharmaceutical Research and Manufacturers of America. (PhRMA).

• Adherium

Adherium Limited (ASX.ADR) is an international Respiratory eHealth company that focuses on solutions for patients, payers, and providers to help them take their medications as prescribed, monitor them remotely, and handle their data.

Adherium's Hailie sensor technology and cloud-based data platform give people real-time feedback on how they use inhaled medications. This makes it easier to treat severe and hard-to-treat asthma and COPD and cuts direct and indirect healthcare costs. Together with their strategic partners, they are making next-generation technology and working to bring value to payers and providers while making the most of the positive reimbursement situation now that remote patient monitoring (RPM) payments are in place.

Adherium's Hailie digital system is made up of patented sensors and proprietary algorithms that track medication delivery, capturing data for clinicians and making auditable reimbursement reports for payers and providers.

The Smart Inhaler Technology market research report is categorized based on type, applications and region.

On the Basis of Type:

• Inhalers
• Dry powdered inhalers (DPIs)  
• Metered dose inhalers (MDI's
• Nebulizers

On the Basis of Application:

• Hospitals
• Clinics
• Home care settings

By Distribution channels:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Further the regions are divided into countries as follows

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Scope of Report

Conclusion 

Smart inhalers are devices that can link to a mobile app through Bluetooth to help patients with chronic breathing problems and improve their quality of life. The number of people with lung diseases like asthma, cystic fibrosis, and chronic obstructive pulmonary disorders, among others, is on the rise, which has led to a huge rise in the demand for smart inhalers. Inhalers that aren't smart aren't as good as ones that are. They include the use of linking technology and sensors, which allow the system as a whole to collect and keep information about the patient's habits and needs. This connectivity technology helps tell patients when their inhalers need to be refilled and when to take their medicine. It can even tell them to take more medicine if their condition worsens. This market is mostly driven by the growing number of people with asthma and COPD. As asthma and other respiratory diseases get worse because of more pollution in the air, more people need smart tracking devices. Chronic obstructive pulmonary disease (COPD) is the third largest cause of death in the world, according to the World Health Organization (WHO). It killed 3.23 million people in 2019, and more than 80% of these deaths happened in low- and middle-income countries. So, these high death rates and unmet medical needs can be reduced by doing more and using smart inhalers. This is a chance for investors to put money into these countries. In 2020, the global market for smart inhaler technology was worth USD 118 million. By 2030, it is projected to be worth USD 1,113.57 million, and it is growing at a CAGR of 25.1% from 2021 to 2030.